RK-APRO
Aprotinin, 30 Trypsin Inhibitory Units (TIU)
Catalog: RK-APRO
5 ml
Size:5 ml
$116
Price: $116
Exendin-4 (Heloderma suspectum) – EIA Kit, CE Mark Certified
- Product Category: ELISA Kits - Assay Kits - RIA Kits, ELISA-EIA
Catalog #: EK-070-94CE
Size: 96 wells
Price: $632
MSDS: View/Download (PDF)
Intra-assay variation: <10%
Inter-assay variation: <15%
Linear Range: 0.08 – 0.86 ng/ml
Sensitivity: 0.08 ng/ml
Sample Extraction:
Cross Reactivity:
| Peptide | % |
| Exendin-4 (Heloderma Suspectum) | 100 |
| Exendin-3 (9-39)-NH2 | 100 |
| Exendin-4 (3-39) | 100 |
| Lixisenatide | 100 |
| Glucagon (Human, Rat, Mouse, Porcine, Bovine) | 0 |
| GLP-1 (7-36)-NH2 (Human, Rat, Mouse) | 0 |
| GLP-1 (7-37) (Human, Rat, Mouse) | 0 |
| GLP-2 (Human) | 0 |
| Oxyntomodulin (Human, Rat, Mouse) | 0 |
Disclaimer: To reduce background noise for this kit, do not add EDTA to your samples.Heparin can be used as an alternative to EDTA for this kit.
No results found.
Links to publications that use this kit:
C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
Tang D, Tian H, Wu J, et al. J Pharmacol Sci. 2018;138(1):23-30.
GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J, Yang K, Xiao W, et al. Peptides. 2018;106:83-90.
The use of low molecular weight protamine to enhance oral absorption of exenatide.
Zhang L, Shi Y, Song Y, et al. Int J Pharm. 2018;547(1-2):265-273.
Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility.
Lee JG, Ryu JH, Kim SM, et al. Biochem Pharmacol. 2018;151:59-68.
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
Chen C, Zheng H, Xu J, Shi X, Li F, Wang X. Daru. 2017;25(1):20.
In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein
Lian Lu, Xiaoqing Su, Yantai Wang et al., RSC Adv., 2017,7, 54178-54187
An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
Kim D, Jeon H, Ahn S, Choi WI, Kim S, Jon S. J Control Release. 2017;256:114-120.
Pyung-Hwan Kim, Minhyung Lee, Sung Wan Kim, Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.
J Control Release. 2012 Aug 20;162(1):9-18. doi: 10.1016/j.jconrel.2012.06.010. Epub 2012 Jun 15.
PLoS ONE. 2012;7(7):e40074.
Nian Gong et al., Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity
Br J Pharmacol. 2011 May; 163(2): 399–412.
Wei Gao et al., Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
J Pharmacol Exp Ther. 2011 March; 336(3): 881–890. doi: 10.1124/jpet.110.175752
Su Young Chaea, Cheng-Hao Jin et al., Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs
Journal of Controlled Release Volume 142, Issue 2, 3 March 2010, Pages 206–213
Kamei et al. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides.
J Control Release. 2009 Feb 27. [Epub ahead of print]
Samson et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.
Mol Ther. 2008 Nov;16(11):1805-12.